Metrics as of 10/15/2026, 04:40 AM (Berlin time), refresh in progress.
Atossa Therapeutics Stock
Atossa Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Steven C. Quay
- Employees
- 16
- Market cap
- $29 M
- IPO
- 08/11/2012
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic…
Atossa Therapeutics stock: price history
1D
+9.8%
1W
+19.3%
1M
+20.2%
6M
-50.1%
YTD
-67.1%
1Y
-81.2%
2Y
-86.8%
5Y
-93.2%
10Y
-99.1%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~35% weaker price swings than usual
Ask the agents about Atossa Therapeutics
Analyst assessment of Atossa Therapeutics
PRICE TARGET LOW
US$10.00
CONSENSUS
US$42.50
MEDIAN
US$42.50
PRICE TARGET HIGH
US$75.00
0
STRONG BUY
4
BUY
1
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 01/10/2026
Atossa Therapeutics stock metrics
P/E
-0.67
P/B
0.97
EV/EBITDA
-0.04
RETURN ON EQUITY
-31.6%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
86.0%
FLOAT SHARES
8,576,571
AVG. DAILY VOLUME (30D)
81,918
Insider transactions (SEC)
Cigler Tessa
Galli Stephen J
Finn Jonathan
Remmel H. Lawrence
Chen Shu-Chih
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Atossa Therapeutics stock
What does Atossa Therapeutics do?
Atossa Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Steven C. Quay, the company employs around 16 people.
The IPO was on 08/11/2012; the stock trades on NASDAQ under the ticker ATOS.
What do analysts say about Atossa Therapeutics stock?
5 analysts rate the stock, the consensus is Buy (as of 01/10/2026).
The average price target is US$42.50, ranging from US$10.00 to US$75.00, with a median of US$42.50.
This is an external assessment, not a statement by Market Jury.
When does Atossa Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -35% stronger than usual.
Does Atossa Therapeutics pay a dividend?
No, Atossa Therapeutics currently does not pay a dividend.
Which stocks are comparable to Atossa Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Atossa Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Atossa Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.